Table 1. Patients’ characteristics.
With liver metastasis | Without liver metastasis | Transfer rate (%) | Z | P | |
---|---|---|---|---|---|
Primary tumor (UICC stage) | |||||
T0 | 0 | 2 | 0.00 | -0.59 | 0.555 |
T1 | 17 | 102 | 14.29 | ||
T2 | 52 | 211 | 19.77 | ||
T3 | 3 | 35 | 7.89 | ||
T4 | 3 | 4 | 42.86 | ||
Lymph node metastasis (UICC stage) | |||||
N0 | 12 | 110 | 9.84 | -3.883 | <0.001 |
N1 | 20 | 112 | 15.15 | ||
N2 | 12 | 65 | 15.58 | ||
N3 | 31 | 67 | 31.63 | ||
TNM staging (UICC stage) | |||||
0 | 0 | 2 | 0.00 | -2.961 | 0.003 |
I | 6 | 43 | 12.24 | ||
II | 24 | 168 | 12.50 | ||
III | 45 | 141 | 24.19 | ||
Immunohistochemical testing | |||||
ER+ | 39 | 171 | 18.57 | -0.347 | 0.729 |
ER- | 45 | 178 | 20.18 | ||
PR+ | 32 | 161 | 16.58 | -0.466 | 0.641 |
PR- | 44 | 188 | 18.97 | ||
HER-2/neu (cerbB-2)+ | 38 | 109 | 25.85 | -3.024 | 0.002 |
HER-2/neu (cerbB-2)- | 34 | 233 | 12.73 |